Literature DB >> 3600459

Subacute pulmonary melioidosis in a temperate climate.

J W Wilson, L R Ashdown, M J Richards, A D Sutherland, J F Cade.   

Abstract

Previous reports of cases of melioidosis that were seen in nonendemic areas of Australia describe recrudescences of latent infection. We describe the case of a patient who presented in the cooler climate of Melbourne with a probable primary, subacute pulmonary infection with Pseudomonas pseudomallei. This case illustrates several points that bear consideration in the management of atypical pneumonia and, more specifically, pulmonary melioidosis. Historical and occupational clues are easily missed or unrecognized, while a persistent growth of gentamicin-resistant Pseudomonas species should arouse suspicion. Septicaemic melioidosis carries a poor prognosis, and treatment should be early and aggressive; use of the newer, third-generation cephalosporin agents should be considered. Given active support in a well-equipped intensive care unit, together with appropriate antibiotic therapy, patients may eventually be cured of this infection, but a high mortality rate is still encountered.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600459     DOI: 10.5694/j.1326-5377.1987.tb133271.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei.

Authors:  L R Ashdown
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 2.  Melioidosis: the tip of the iceberg?

Authors:  D A Dance
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

3.  Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Authors:  Ediane B Silva; Andrew Goodyear; Marjorie D Sutherland; Nicole L Podnecky; Mercedes Gonzalez-Juarrero; Herbert P Schweizer; Steven W Dow
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.